Moderna's SPIKEVAX Gains FDA-Required Boxed Warning Update for Myocarditis and Pericarditis Risk

A labeling change approved by FDA on June 25, 2025 adds a required updated boxed warning to SPIKEVAX and other mRNA COVID-19 vaccines, formally codifying myocarditis and pericarditis as post-vaccination risks, a move that extends post-market labeling obligations for Moderna Tx, Inc. and sets a compliance reference point for regulatory affairs teams across the mRNA vaccine sector.

The update follows a sequence of approval actions documented in SPIKEVAX's regulatory file, with supporting memoranda from the Center Director and Chair Review issued through September 26, 2025. That documentation trail reflects the layered review process under 21 CFR Part 601 governing biologics labeling revisions, and signals that FDA's pharmacovigilance posture on cardiac adverse events remains active rather than resolved.

For QA directors and regulatory leads at vaccine manufacturers, the practical read is straightforward: a required labeling change of this class, boxed warning, triggers downstream obligations across package insert version control, lot release documentation, and pharmacovigilance reporting workflows. Teams operating under ICH E2C periodic benefit-risk evaluation report schedules should confirm that the myocarditis/pericarditis signal is accurately reflected in the next reporting cycle.

SPIKEVAX carries approval for active immunization against COVID-19 caused by SARS-CoV-2 in individuals 65 years and older, and in those aged 6 months through 64 years with at least one underlying condition placing them at high risk for severe outcomes. The narrowed indication scope, established through prior approval letters dating to January 2022, provides the population context within which the cardiac risk signal is being communicated.

The density of approval letters in the SPIKEVAX regulatory file, spanning January 2022 through August 2025, illustrates the iterative labeling maintenance burden that accompanies a post-pandemic biologics license, and the boxed warning addition represents the most significant safety communication tier available under current FDA labeling regulations.

Regulatory affairs leads at other mRNA platform manufacturers should treat the June 2025 action as a signal to audit their own labeling currency against FDA's current safety determinations, particularly where shared platform technology creates analogous pharmacovigilance exposure.

The measurable compliance checkpoint now sits at confirmed package insert alignment with the June 25, 2025 boxed warning language across all distributed SPIKEVAX presentations.

Source: FDA Vaccines, Blood and Biologics product page via What's New Vaccines Blood Biologics RSS Feed, published May 22, 2026; supporting documents include Chair Review Memorandum dated September 26, 2025 and multiple approval letters spanning 2022–2025.